Cannabidiol (CBD) as a novel treatment in the early phases of psychosis

@article{Chesney2021CannabidiolA,
  title={Cannabidiol (CBD) as a novel treatment in the early phases of psychosis},
  author={Edward Chesney and Dominic Oliver and Philip McGuire},
  journal={Psychopharmacology},
  year={2021},
  volume={239},
  pages={1179 - 1190}
}
The pharmacological interventions available for individuals in the early stages of psychosis are extremely limited. For those at clinical high risk for psychosis, there is no licensed treatment available. For those with first-episode psychosis, all licensed antipsychotic medications act via dopamine D2 receptors. While treatment with antipsychotics is transformative in some patients, in others, it is ineffective. In addition, these medications can often cause adverse effects which make patients… 

References

SHOWING 1-10 OF 129 REFERENCES
Antipsychotic Interventions in Prodromal Psychosis
TLDR
In the absence of sufficient evidence-based knowledge to guide treatment, definitive clinical recommendations and guidelines cannot be derived and longer term clinical trials with a larger number of patients are needed to determine the effectiveness of antipsychotic intervention and the relationship of its duration to emergence of adverse events.
Cannabidiol for the treatment of psychosis in Parkinson’s disease
TLDR
Preliminary data suggest that CBD may be effective, safe and well tolerated for the treatment of the psychosis in PD.
17.3 EFFECT OF CANNABIDIOL ON SYMPTOMS, DISTRESS AND NEUROPHYSIOLOGICAL ABNORMALITIES IN CLINICAL HIGH-RISK FOR PSYCHOSIS PATIENTS: A PLACEBO-CONTROLLED STUDY
TLDR
Results from the proof-of-concept study suggest that 3-week treatment with CBD has beneficial effects on anxiety, attenuated psychotic symptoms and the distress associated with psychotic symptoms, and suggest that short-term treatment with cannabidiol modulates both medial temporal and striatal function in CHR patients, regions that are critically implicated in the CHR state.
Cannabidiol monotherapy for treatment-resistant schizophrenia
TLDR
The preliminary data suggest that CBD monotherapy may not be effective for TRS, and patients with treatment-resistant schizophrenia should be switched to olanzapine for over 15 days.
Cannabidiol (CBD) as an Adjunctive Therapy in Schizophrenia: A Multicenter Randomized Controlled Trial.
TLDR
Findings suggest that CBD has beneficial effects in patients with schizophrenia, and this agent may represent a new class of treatment for the disorder.
Remission of severe, treatment-resistant schizophrenia following adjunctive cannabidiol
  • C. Makiol, M. Kluge
  • Medicine, Psychology
    The Australian and New Zealand journal of psychiatry
  • 2019
TLDR
This case report contradicts the assumption ‘that CBD is not likely to be any superior than existing antipsychotics’ (Gururajan and Malone, 2016) and suggests CBD might be particularly suitable for those patients being resistant to antipsychotic due to its different mode of action.
Effects of short-term cannabidiol treatment on response to social stress in subjects at clinical high risk of developing psychosis
TLDR
The findings show that it is worthwhile to design further well powered studies which investigate whether CBD may be used to affect cortisol response in clinical high risk for psychosis patients and any effect this may have on symptoms.
The effects of cannabidiol (CBD) on cognition and symptoms in outpatients with chronic schizophrenia a randomized placebo controlled trial
TLDR
At the dose studied, CBD augmentation was not associated with an improvement in MCCB or PANSS scores in stable antipsychotic-treated outpatients with schizophrenia, and CBD was well tolerated with no worsening of mood, suicidality, or movement side effects.
A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia.
TLDR
In this 4-week trial involving patients with an acute exacerbation of schizophrenia, SEP-363856, a non-D2-receptor-binding antipsychotic drug, resulted in a greater reduction from baseline in the PANSS total score than placebo.
...
1
2
3
4
5
...